Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745357 | PMC |
| http://dx.doi.org/10.1212/NXI.0000000000000433 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion.
Neurol Sci
December 2024
School of Clinical Methodology, IRCCS "Sacred Heart - Don Calabria", Negrar Di Valpolicella, Italy.
Article Synopsis
- * Current treatments can have side effects and don't always work well for everyone, so there's a big need for better options.
- * A new drug called eculizumab has been approved in Italy and might help those who don’t respond to standard treatments, and experts think it could meet the needs of many patients with MG.
Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma.
Neurohospitalist
January 2022
Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
Opsoclonus myoclonus syndrome (OMS) is a rare immune-mediated paraneoplastic or para/-post-infectious syndrome characterized by "dancing" eye movements, myoclonus, and ataxia. Neuropsychiatric symptoms have also been reported. Without treatment, OMS may progress to further neurological impairment and even death.
View Article and Find Full Text PDFAbsence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome.
Neurology
February 2021
From the Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) (M.P.-P., M.G., T.A., A.S., F.G., J.D.), and Neurology Service (M.G., T.A., A.S., J.D.), Hospital Clínic, and Pediatric Neuroimmunology Unit, Department of Pediatric Neurology (T.A., C.L.), and Department of Haematology and Oncology (A.M.L.M.), Sant Joan de Déu Children Hospital, Universitat de Barcelona; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER) (M.P.-P., M.G., T.A., J.D.), Valencia; Developmental Tumor Biology Laboratory (C.L.), Sant Joan de Déu Research Institute, Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain. M.P.P. is currently affiliated with the Université de Bordeaux, CNRS, Interdisciplinary Institute for Neuroscience, IINS, UMR 5297, France.
Objective: A recent study showed glutamate receptor delta 2 antibodies (GluD2-ab) in sera of patients with opsoclonus-myoclonus syndrome (OMS). Inconsistencies between cerebellar immunoreactivity and expression of GluD2 led us to hypothesize that these antibodies are not biomarkers of OMS.
Methods: Serum of 45 children with OMS (10 [22%] with neuroblastoma), 158 adults with OMS (53 [34%] with tumors), and 172 controls including 134 patients with several types of neurologic disorders, 18 with neuroblastoma without OMS, and 20 healthy participants were investigated.
NMDA receptor antibody in teratoma-related opsoclonus-myoclonus syndrome.
J Clin Neurosci
December 2018
Department of Immunology, Royal Prince Alfred Hospital, Sydney, Australia.
Opsoclonus-myoclonus syndrome (OMS) is a brainstem/cerebellar syndrome producing disabling multi-directional saccadic oscillations with oscillopsia, with or without somatic myoclonus and cerebellar ataxia (Wong et al., 2001; Armangué et al., 2016).
View Article and Find Full Text PDFNeuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma.
Neurol Neuroimmunol Neuroinflamm
March 2018
National Pediatric Myoclonus Center (M.R.P., N.R.M.); and National Pediatric Neuroinflammation Organization, Inc. (M.R.P.), Orlando, FL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!